Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
04 2019
Historique:
received: 03 11 2017
revised: 18 07 2018
accepted: 28 09 2018
pubmed: 16 12 2018
medline: 10 10 2020
entrez: 16 12 2018
Statut: ppublish

Résumé

Progress in radiation treatment of head and neck squamous cell carcinoma (HNSCC) deserves the studies focused on molecular predictors that would help to enhance individually tailored treatment. p16/epidermal growth factor receptor (EGFR)/cluster of differentiation-44 (CD44) was immunohistochemically analyzed in 165 HNSCC patients. In the entire group and the p16 negative cohort, better 3-year overall survival and locoregional control correlated with p16 positivity, CD44, and EGFR negativity were observed. Combined analysis revealed the worst results in the CD44+/p16-, EGFR+/p16-, and EGFR+/CD44+ groups and in the EGFR+/CD44+ within p16 negative cohort. Multivariate analysis found tumor stage, Karnofsky index, p16, and CD44 as prognostic factors of overall survival and clinical stage, and p16 as a prognostic factor for locoregional control. Clinical stage and Karnofsky index affected overall survival and tumor stage. EGFR affected locoregional control in the p16 negative subgroup. Our study confirmed the negative effect of CD44 and EGFR and the positive effect of p16 on radiotherapy results.

Sections du résumé

BACKGROUND
Progress in radiation treatment of head and neck squamous cell carcinoma (HNSCC) deserves the studies focused on molecular predictors that would help to enhance individually tailored treatment.
METHODS
p16/epidermal growth factor receptor (EGFR)/cluster of differentiation-44 (CD44) was immunohistochemically analyzed in 165 HNSCC patients.
RESULTS
In the entire group and the p16 negative cohort, better 3-year overall survival and locoregional control correlated with p16 positivity, CD44, and EGFR negativity were observed. Combined analysis revealed the worst results in the CD44+/p16-, EGFR+/p16-, and EGFR+/CD44+ groups and in the EGFR+/CD44+ within p16 negative cohort. Multivariate analysis found tumor stage, Karnofsky index, p16, and CD44 as prognostic factors of overall survival and clinical stage, and p16 as a prognostic factor for locoregional control. Clinical stage and Karnofsky index affected overall survival and tumor stage. EGFR affected locoregional control in the p16 negative subgroup.
CONCLUSION
Our study confirmed the negative effect of CD44 and EGFR and the positive effect of p16 on radiotherapy results.

Identifiants

pubmed: 30552846
doi: 10.1002/hed.25533
doi:

Substances chimiques

CD44 protein, human 0
Hyaluronan Receptors 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

940-949

Subventions

Organisme : Ministry of Health of the Czech Republic, by the Czech Health Research Council project, No. 15-31627A
Pays : International

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Marek Slavik (M)

Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

Tetiana Shatokhina (T)

1st Department of Pathological Anatomy, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Jiri Sana (J)

Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Parwez Ahmad (P)

Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Tomas Kazda (T)

Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Iveta Selingerova (I)

Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic.

Marketa Hermanova (M)

1st Department of Pathological Anatomy, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Renata Cervena (R)

Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

Tomas Novotny (T)

Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

Petr Burkon (P)

Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

Pavel Smilek (P)

Department of Otorhinolaryngology and Head and Neck Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Zuzana Horakova (Z)

Department of Otorhinolaryngology and Head and Neck Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Pavel Slampa (P)

Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

Ondrej Slaby (O)

Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH